Nymox claims “success” in Phase II trial of NX-1207 in low-risk prostate cancer

According to a media release issued today by Nymox Pharmaceutical Corp., their investigational drug NX-1207 (now properly known by the generic name fexapotide triflutate) successfully met the designated endpoints for a Phase II clinical trial of this drug in treatment of men with low-grade, localized prostate cancer. … READ MORE …

ED drugs and risk for prostate cancer recurrence? … NOT!

Back in February 2015 a group of German researchers published a study suggesting that there was a small but significantly increased risk of biochemical recurrence after prostate cancer treatment among men using drugs like sildenafil (Viagra) to recover/stimulate erectile function. … READ MORE …

Publication of final data from the TRAPEZE trial

Some 2½ years ago, James presented data from the TRAPEZE trial at the annual meeting of the American Society of Clinical Oncology in Chicago. At the time, we described these data as “unsurprising.” … READ MORE …

Nine-year outcomes after treatment with SBRT

Katz and Kang will present their 9-year outcomes on 515 patients treated by stereotactic body radiation therapy (SBRT) at the Genitourinary Cancers Symposium tomorrow … READ MORE …

Unexpected and perhaps intriguing data from the STAMPEDE trial

In a poster presentation to be given at the upcoming Genitourinary Cancers Symposium in San Francisco later this week, data from the STAMPEDE trial in the UK appear to have demonstrated a result that few people seem to have expected. … READ MORE …

Long-term survival of high-risk patients < 60 years of age treated by radical prostatectomy

A multi-institutional, international study has provided us with data on the 10-, 15-, and 20-year survival of a cohort of 600 relatively young, high-risk prostate cancer patients, all of whom were treated with first-line radical prostatectomy. … READ MORE …

Focal therapy of just the index or primary lesion

A newly published paper in European Urology has provided us with data from one of the earliest, well-documented series of patients undergoing focal therapy of the index lesion from what is known to have been multifocal prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,369 other followers